Clinical trials: DGF, open to volunteers
Delayed Graft Function, Kidney Transplantation
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
Delayed graft function, defined as the need for dialysis within seven days of kidney transplantation, is a common complication affecting deceased-donor kidney transplant recipients.
- Trial name
- NCT07726134
- Testing
- Furosemide, Mannitol
- Where
- 2 sites in Canada
- Volunteers
- 160 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Delayed Graft Function, Kidney Transplantation
The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients
This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant…
- Trial name
- NCT07275632
- Testing
- Vonoprazan fumarate
- Where
- 2 sites in China
- Volunteers
- 47 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Delayed Graft Function, DGF
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after…
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Trial name
- AWAKE (NCT06830798)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 16 more
- Volunteers
- 450 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Kidney Transplant; Complications, Liver Transplant; Complications
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after…
- Trial name
- DARE (NCT06130046)
- Testing
- MR-proADM dosage
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Rome Tor Vergata